206 related articles for article (PubMed ID: 17121915)
1. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
[TBL] [Abstract][Full Text] [Related]
2. A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Oh SH; Kang JH; Kyu Woo J; Lee OH; Kim ES; Lee HY
Int J Cancer; 2012 Aug; 131(3):537-47. PubMed ID: 22113431
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
4. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases.
Angelloz-Nicoud P; Harel L; Binoux M
Growth Regul; 1996 Sep; 6(3):130-6. PubMed ID: 8894645
[TBL] [Abstract][Full Text] [Related]
7. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
8. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer.
Hochscheid R; Jaques G; Wegmann B
J Endocrinol; 2000 Sep; 166(3):553-63. PubMed ID: 10974650
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I (IGF-I) regulates IGFBP-3 and IGFBP-4 by multiple mechanisms in A549 human adenocarcinoma cells.
Price WA; Moats-Staats BM; Stiles AD
Am J Respir Cell Mol Biol; 1995 Oct; 13(4):466-76. PubMed ID: 7546777
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
Kim JH; Choi DS; Lee OH; Oh SH; Lippman SM; Lee HY
Blood; 2011 Sep; 118(9):2622-31. PubMed ID: 21551235
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
Dunn SE; Torres JV; Oh JS; Cykert DM; Barrett JC
Cancer Res; 2001 Feb; 61(4):1367-74. PubMed ID: 11245436
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells.
Kim HS; Ingermann AR; Tsubaki J; Twigg SM; Walker GE; Oh Y
Cancer Res; 2004 Mar; 64(6):2229-37. PubMed ID: 15026367
[TBL] [Abstract][Full Text] [Related]
14. Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro.
Wang X; Jiang Z; An J; Mao X; Lin F; Sun P
Mol Med Rep; 2018 Mar; 17(3):4273-4280. PubMed ID: 29328476
[TBL] [Abstract][Full Text] [Related]
15. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
16. Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model.
Shukla S; MacLennan GT; Fu P; Gupta S
Pharm Res; 2012 Jun; 29(6):1506-17. PubMed ID: 22139534
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-1 elevates urokinase-type plasminogen activator-1 in human breast cancer cells: a new avenue for breast cancer therapy.
Dunn SE; Torres JV; Nihei N; Barrett JC
Mol Carcinog; 2000 Jan; 27(1):10-7. PubMed ID: 10642432
[TBL] [Abstract][Full Text] [Related]
18. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells.
Rao JS; Gondi C; Chetty C; Chittivelu S; Joseph PA; Lakka SS
Mol Cancer Ther; 2005 Sep; 4(9):1399-408. PubMed ID: 16170032
[TBL] [Abstract][Full Text] [Related]
20. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
